MNT -- New data indicate that patients with metabolic syndrome have a greater likelihood of reaching specified lipid and high-sensitivity C-reactive protein (hs-CRP) levels if they are treated with ezetimibe/simvastatin than with atorvastatin.
MNT -- New data indicate that patients with metabolic syndrome have a greater likelihood of reaching specified lipid and high-sensitivity C-reactive protein (hs-CRP) levels if they are treated with ezetimibe/simvastatin than with atorvastatin.